2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1071

Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis
Abstract Number: 12

Protein Phosphatase 2A, a Serine/Threonine Phosphatase, Is Essential for Optimal B Cell Function
Abstract Number: 761

Protein/Creatinin Urinary Index Has Concordance with 24 Hour Urinary Proteinuria in Patients with Systemic Lupus Erythematosus
Abstract Number: 1832

Proteomic and Transcriptomic Profiling of Cells in Ankylosing Spondylitis Patients Identifies a Novel, Synovial-Resident CD8+ T Cell
Abstract Number: 1114

Proteomic Aptamer Analysis Reveals a Distinct Profile of Very Early Systemic Sclerosis (SSc) Patients at Risk for Progression Toward Definite SSc
Abstract Number: 1332

Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
Abstract Number: 2223

Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study
Abstract Number: 2178

Provider Perceptions of Telerheumatology within the Veterans Health Administration: A National Survey Study
Abstract Number: 1643

Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
Abstract Number: 964

Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies
Abstract Number: 1653

Psychological Distress in Patients with Axial Spondyloarthritis in Europe. Results from the European Map of Axial Spondyloarthritis Survey
Abstract Number: 1600

Psychometric Properties of the Assessment of Spa International Society Health Index in Patients with Active As/Radiographic Axial Spa in a Phase 3 Clinical Study
Abstract Number: 348

Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus
Abstract Number: 2894

Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Abstract Number: 1138

Public Health Impact of Physical Inactivity in the Knee OA Population in the US

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].